NIH – Psychedelics as Therapeutics: Gaps, Challenges and Opportunities

O workshop organizado pelo National Institutes of Health (EUA) sobre psicadélicos como abordagem terapêutica para a promoção da saúde mental apresentou um programa abrangente, abordando os mecanismos de ação dos psicadélicos, os contextos propícios à promoção de efeitos terapêuticos, e a necessidade de psicoterapias concomitantes. Os vídeos da conferência estão disponíveis (links nos títulos) e incluem os seguintes temas e palestrantes:

Tema 1 – Investigação Básica e Translacional ‌

• Psychedelics for Mental Health: Translating Preclinical Data Into Clinical Practice
  Gabriella Gobbi, McGill University
   
• The Promises and Perils of Psychedelic Pharmacology
  Bryan Roth, University North Carolina
   
• How Informative are Preclinical Models of Psychedelic Drug Mechanisms? From 5-HT2A to Another Place far Away
  Clint Canal, Mercer University
   
• Optimizing Psychedelics for Treating Neuropsychiatric Disease: The Preclinical Perspective
  Scott Thompson, University of Maryland
   
• 5-HT2AR PET Imaging and Functional Connectivity
  Gitte Knudsen, University of Copenhagen
   
• Discussion Leader Talk
  Rob Malenka, Stanford University

Tema 2 – Ensaios Clínicos ‌

• Does Subjective Experience Mediate the Putative Therapeutic Effects of Psychedelics?
  Michael Bogenschutz, New York University
   
• Safety and Efficacy of MDMA for the Treatment of PTSD
  Jennifer Mitchell, University of California San Francisco
   
• Psilocybin and Smoking Cessation
  Matthew Johnson, Johns Hopkins University
   
• Ketamine Assisted Psychotherapy in the Treatment of Alcohol Use Disorder and Other Addictions
  Celia Morgan, University of Exeter
   
• MDMA Trial Design, What Have We Learned?
  Michael Mithoefer, Medical University South Carolina
   
• Discussion Leader Talk
  Elias Dakwar, Columbia University

Tema 3 – O Futuro: Limitações dos Estudos Atuais e Consequências para o Uso em Situação Real

• Set and Settings in Psychedelic Clinical Trials and Moving Forward
  Ido Hartogsohn, Bar-Ilan University
   
• Overcoming Confounds in Psychedelic Clinical Trials: Designs and Measurement
  Suresh Muthukumaraswamy, University of Auckland
   
• Ethical Considerations in Conducting Psychedelic Research
  Paul Appelbaum, Columbia University
   
• Considerations of Study Design and Interaction of Medication and Medical Practice in Drug Registration Trials
  Javier Muniz, U.S. Food and Drug Administration
   
• Discussion Leader Talk
  Susan Learned, Independent Pharmaceutical Consultant
   
• Director’s Summation and Closing Remarks
  Nora Volkow, National Institute on Drug Abuse